Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 2/20 | 0.53 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | JAK1 | P23458 | 1/20 | 0.48 |
| ▸ | NAMPT | P43490 | 1/20 | 0.47 |
| ▸ | HTR6 | P50406 | 1/20 | 0.46 |
| ▸ | GRM1 | Q13255 | 8/20 | 0.45 |
| ▸ | GRM5 | P41594 | 7/20 | 0.45 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.45 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12965676 | 0.88 | GRM1 (0.52) | CNR1PDK4JAK1NAMPTHTR6 | |
| SCHEMBL6629695 | 0.88 | PDK4 (0.52) | CNR1PDK4JAK1NAMPTHTR6 | |
| SCHEMBL4825697 | 0.86 | CNR1 (0.54) | CNR1PDK4JAK1NAMPTHTR6 | |
| SCHEMBL23240953 | 0.85 | CNR1 (0.55) | CNR1PDK4JAK1NAMPTHTR6 | |
| SCHEMBL8075949 | 0.85 | PDK4 (0.64) | CNR1PDK4JAK1NAMPTHTR6 | |
| SCHEMBL30736543 | 0.85 | PDK4 (0.64) | CNR1PDK4JAK1NAMPTHTR6 | |
| SCHEMBL19701841 | 0.85 | CNR1 (0.55) | CNR1PDK4JAK1NAMPTHTR6 | |
| SCHEMBL4433323 | 0.85 | MAPT (0.52) | CNR1MAPT | |
| SCHEMBL15556190 | 0.84 | CNR1 (0.55) | CNR1PDK4JAK1NAMPTHTR6 | |
| SCHEMBL31342210 | 0.84 | CNR1 (0.55) | CNR1PDK4JAK1NAMPTHTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8759342-B2 | Benzo[1,4]oxazin-3-one, benzo[1,4]thiazin-3-one and quinolin-2-one urotensin II receptor antagonists | JANSSEN PHARMACEUTICA NV (BE) | 2014-06-24 | — | — | US | disclosed |
| US-8759342-B2 | Benzo[1,4]oxazin-3-one, benzo[1,4]thiazin-3-one and quinolin-2-one urotensin II receptor antagonists | JANSSEN PHARMACEUTICA NV (BE) | 2014-06-24 | — | — | US | disclosed |
| US-8759342-B2 | Benzo[1,4]oxazin-3-one, benzo[1,4]thiazin-3-one and quinolin-2-one urotensin II receptor antagonists | JANSSEN PHARMACEUTICA NV (BE) | 2014-06-24 | — | — | US | disclosed |
| US-20080039454-A1 | Urotensin II receptor antagonists | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080039454-A1 | Urotensin II receptor antagonists | UTS2R, PLAUR, NTSR2 | CNR1 246/4885PDK4 4833/4885MAPT 1633/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.